IL161388A0 - Method of reducing type 2 diabetes in high risk patients - Google Patents

Method of reducing type 2 diabetes in high risk patients

Info

Publication number
IL161388A0
IL161388A0 IL16138802A IL16138802A IL161388A0 IL 161388 A0 IL161388 A0 IL 161388A0 IL 16138802 A IL16138802 A IL 16138802A IL 16138802 A IL16138802 A IL 16138802A IL 161388 A0 IL161388 A0 IL 161388A0
Authority
IL
Israel
Prior art keywords
diabetes
high risk
risk patients
reducing type
reducing
Prior art date
Application number
IL16138802A
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL161388A0 publication Critical patent/IL161388A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL16138802A 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients IL161388A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34449501P 2001-10-17 2001-10-17
PCT/EP2002/011636 WO2003032963A2 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients

Publications (1)

Publication Number Publication Date
IL161388A0 true IL161388A0 (en) 2004-09-27

Family

ID=23350759

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16138802A IL161388A0 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients

Country Status (7)

Country Link
EP (1) EP1438043A2 (en)
JP (1) JP2005531492A (en)
AU (1) AU2002335843A1 (en)
CA (1) CA2463682A1 (en)
IL (1) IL161388A0 (en)
MX (1) MXPA04003022A (en)
WO (2) WO2003032963A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
US20050065184A1 (en) * 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
MX2009002091A (en) * 2006-08-28 2009-03-09 Sanofi Aventis Deutschland Methods of lowering glucose levels.
SI2970123T1 (en) 2013-03-14 2019-12-31 Amgen Inc. Salt of omecamtiv mecarbil and process for preparing salt
CA2916698C (en) * 2013-06-26 2021-03-09 Dong-A St Co., Ltd Composition for preventing or treating renal diseases, containing dpp-iv inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A3 (en) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Use of ace inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
SE9903028D0 (en) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Also Published As

Publication number Publication date
WO2003032965A3 (en) 2003-11-27
EP1438043A2 (en) 2004-07-21
MXPA04003022A (en) 2004-07-05
WO2003032963A2 (en) 2003-04-24
WO2003032965A2 (en) 2003-04-24
AU2002335843A1 (en) 2003-04-28
CA2463682A1 (en) 2003-04-24
WO2003032963A3 (en) 2003-12-24
JP2005531492A (en) 2005-10-20

Similar Documents

Publication Publication Date Title
EP1416961A4 (en) Composition and method for the treatment of disease
GB0110288D0 (en) Composition and treatment method
AU2002315094A1 (en) Method and apparatus for improved patient care
AU2002233670A1 (en) Process for producing perfluorocarbons and use thereof
AU2002327430A8 (en) Methods for treating diabetes and other blood sugar disorders
AU2002251982A1 (en) Orthopedic implant and method for orthopedic treatment
AU2002326600A1 (en) Side-exit catheter and method for its use
HK1070849A1 (en) Catheter and use method thereof
EP1425021A4 (en) Physiological method of improving vision
AU2003232044A8 (en) Composition and method for dermatological treatment
IL161073A0 (en) Composition and method for treating diabetes
AU2002367023A8 (en) Compositions and methods for treating heart failure
AU2002365057A8 (en) Compositions and methods for treating heart failure
SI1399424T1 (en) Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide
GB0126643D0 (en) Composition and process
HK1069829A1 (en) Surface treatment composition and method
IL161388A0 (en) Method of reducing type 2 diabetes in high risk patients
EP1435962A4 (en) Treatment of type i diabetes
EP1427429A4 (en) Compositions and methods for treating subjects with hyperglycemia
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
IL156655A0 (en) Hormone replacement therapy method and its administration form
GB0127618D0 (en) "Composition and method for treatment of wounds"
AU2003228787A8 (en) Composition and method for reducing post-prandial blood glucose
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
GB0107033D0 (en) Method and composition